Loading
Adding low-dose rucaparib to cisplatin did not significantly improve the main outcome after surgery. Limited drug exposure makes this an incomplete test of other PARP strategies.
Randomized postoperative TNBC or BRCA-mutated breast trial with residual invasive tumour greater than 2 cm or persistent nodal involvement after neoadjuvant therapy. Patients received cisplatin alone or with low-dose rucaparib; accrual occurred in 2010 to 2013.
Negative result for the tested low-exposure combination; not proof that every rucaparib or PARP strategy fails.
Shares Rucaparib, PARP, Triple-negative breast cancer (TNBC).
Shares PARP, Breast cancer (all types), Triple-negative breast cancer (TNBC).
Shares PARP, Breast cancer (all types), Triple-negative breast cancer (TNBC).
Shares PARP, Breast cancer (all types), Triple-negative breast cancer (TNBC).
Shares PARP, Breast cancer (all types), Triple-negative breast cancer (TNBC).
Shares PARP, Breast cancer (all types), Triple-negative breast cancer (TNBC).
Shares PARP, Breast cancer (all types), Triple-negative breast cancer (TNBC).
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/